Centessa Pharmaceuticals plc (CNTA)
NMS – Real vaqt narxi. Valyuta: USD
39.61
+0.02 (0.05%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NMS – Real vaqt narxi. Valyuta: USD
39.61
+0.02 (0.05%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Centessa Pharmaceuticals plc, sho'ba korxonalari bilan birgalikda, Buyuk Britaniya va Qo'shma Shtatlarda oreksin asosidagi nevrologiya terapiyalarini kashf qiladi, ishlab chiqadi va yetkazib beradi. Kompaniya ORX750ni ishlab chiqadi, bu oreksin retseptor 2 agonisti bo'lib, markaziy giperinsomniya buzilishlarini, jumladan, narkolepsiya 1 va 2-tipi, shuningdek, idiopatik giperinsomniyani davolash uchun IIa faza klinik sinovida. Kompaniya, shuningdek, nevrologik va neyrodegenerativ kasalliklarni davolash uchun I faza klinik sinovida bo'lgan ORX142; nevropsixiatrik kasalliklarni davolash uchun I faza klinik sinovida bo'lgan ORX489; va LockBody, erta bosqichdagi immuno-onkologiya dasturi texnologiyasi platformasini ishlab chiqish bilan shug'ullanadi. Kompaniya 2020 yilda tashkil etilgan va shtab-kvartirasi Buyuk Britaniyaning Altrincham shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Chief Business Officer |
| Dr. Kimberly A. McCormick Pharm.D. | Senior Vice President of Regulatory Affairs & Medical Writing |
| Dr. Mario Alberto Accardi Ph.D. | CEO & Director |
| Dr. Stephen J. Kanes M.D., Ph.D. | Head of R&D and Chief Medical Officer |
| Mr. Iqbal J. Hussain L.L.B. | Chief Legal Officer, Chief Compliance Officer & Company Secretary |
| Ms. Charlene Stoudt |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | DEFM14A | d148719ddefm14a.htm |
| 2026-05-05 | 10-Q | cnta-20260331.htm |
| 2026-04-29 | DEF 14A | cnta-20260428.htm |
| 2026-04-29 | ARS | centessaars-123125.pdf |
| 2026-04-17 | PREM14A | d148719dprem14a.htm |
| 2026-04-13 | DEFA14A | d20845ddefa14a.htm |
| 2026-03-31 | DEFA14A | d86726ddefa14a.htm |
| 2026-02-13 | 8-K | d932267d8k.htm |
| 2026-01-07 | 8-K/A | d51805d8ka.htm |
| 2025-12-11 | 8-K | d933269d8k.htm |
| Senior Vice President of Clinical Development Operations |
| Ms. Karen M. Anderson | Chief People Officer |
| Ms. Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations & Corporate Communications |
| Ms. Tia L. Bush | Chief Technology & Quality Officer |